Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COMPliance with Avonex PS in patients with relapsing-remitting MS

Trial Profile

COMPliance with Avonex PS in patients with relapsing-remitting MS

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Biogen Idec
  • Most Recent Events

    • 27 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2011 Planned end date changed from Feb 2011 to Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top